Anji is a technology transfer professional with more than 20 years’ experience of working with early-stage, translational life science research. Anji has extensive experience of IP related transactions and management, including, licensing, strategic partnership, funding, business development of healthcare technologies and development of knowledge transfer policies. Her current role at LifeArc involves working with academic and charitable establishments toidentify, cultivate and commercialize early-stage healthcare technologies. As the LifeArc Lead for the Innovation Hubs for Gene Therapies, she leads activities to ensure viral advanced therapies are developed to impact patients.
As a proponent for professional advancement in technology transfer, Anji is Program Director for the LifeArc Technology Transfer and the LifeArc AUTM Training Fellowship programs. These two unique training programs have been designed to train and assist scientists to become technology transfer professionals. Anji is also head of translational STEM skills within the Academic Engagement Team at LifeArc. A team who through partnership with academia and industry, is missioned to promote STEM skills, training, and engagement of STEM students from underrepresented backgrounds to learn about Life Science related careers.
An advocate of equality diversity and Inclusion (EDI), Anji cofounded Global Equality, Diversity, and Inclusion in Technology Transfer (GEDITT), an initiative with a mission to raise awareness and promote EDI in the technology transfer sector. She also works closely with industry, academia, and associations to implement ED&I strategies and policies.
Anji holds an M.Sc. in Human Molecular Genetics and Ph.D. in Cancer Genetics from Imperial College, as well as an M.Sc. and Certificate in Intellectual Property Law from Queen Mary, University of London.She is a certified project manager (PRINCE2), registered technology transfer professional (RTTP) and a certified licensing professional (CLP).
Anji sits on the boards of AUTM, ASTP, and is a member of the BioIndustry Association (BIA) Cell & Gene Therapy Advisory Committee, and AUTM Equity, Diversity & Inclusion Committee.